Please assess the completion status of the following clinical trial:

Trial Title: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infection~2. The absence of exclusionary resistance mutations on a genotypic resistance assay~3. Antiretroviral (ARV) drug-naïve~4. Screening HIV-1 RNA \>1000 copies/mL~5. Screening CD4+ T-cell count \< 200 cells/ml~6. Laboratory values obtained within 30 days prior to study entry.~   * Absolute neutrophil count (ANC) \>500/mm3~  * Hemoglobin \>8.0 g/dL~  * Platelet count \>40,000/mm3~  * AST (SGOT), ALT (SGPT), and alkaline phosphatase \<5 x ULN~  * Total bilirubin \<2.5 x ULN~  * Calculated creatinine clearance ≥60 mL/min (by Cockcroft-Gault equation)~7. For women of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to initiating study medications.~8. Contraception requirements~9. Men and women age \>18 years and \< 60 years.~10. Ability and willingness of subject or legal guardian/representative to give written informed consent.~Exclusion Criteria:~1. Currently breast-feeding.~2. Use of immunomodulators, vaccines, growth hormone, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry.~3. Known allergy/sensitivity to study drugs, pneumococcal polysaccharide vaccine, tetanus-diphtheria vaccine~4. Receipt of pneumococcal polysaccharide vaccine or tetanus-diphtheria vaccine in the past 5 years.~5. Active drug or alcohol use or dependence~6. Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 14 days prior to study entry.~7. Requirement for any current medications that are prohibited with any study treatment.~8. Evidence of any major resistance-associated mutation on any genotype or evidence of significant resistance on any phenotype performed at any time prior to study entry~9. Current or anticipated imprisonment or involuntary incarceration in a medical facility for psychiatric or physical (e.g., infectious disease) illness~10. History of, or current bipolar disorder, major depression, schizophrenia or other psychotic disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ARM A/Lopinavir/ritonavir (Type: ACTIVE_COMPARATOR): Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
- ARM B/Efavirenz (Type: ACTIVE_COMPARATOR): Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).